Navigation Links
Thoratec Announces Resignation of Chief Financial Officer
Date:6/10/2011

PLEASANTON, Calif., June 10, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that David V. Smith, Executive Vice President and Chief Financial Officer, has resigned from his position in order to pursue other business opportunities.  Mr. Smith will remain with Thoratec through July 1st and assist in the transition process.

"Over the past several years, David has played a key role in building a world-class financial infrastructure at Thoratec, which positions the company well to support continued strong performance.  We thank him for his contributions and wish him well in his future endeavors," said Gary F. Burbach, President and Chief Executive Officer.

In conjunction with today's announcement, Thoratec is reiterating its previously issued 2011 financial guidance.

Roxanne Oulman, Vice President of Finance, will serve as interim Chief Financial Officer until a permanent replacement is named.  Ms. Oulman joined Thoratec in 2004 and has assumed increasing levels of responsibility since that time.  

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation.

Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2011 financial results or future performance, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address issues raised by FDA inspections adequately and on a timely basis without a results recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, and in Thoratec's first quarter 2011 quarterly report on Form 10-Q and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Announces Presentations at Upcoming Investor Conferences
2. Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology
3. Thoratec Presentation at Bank of America Conference to be Webcast
4. Thoratec Reports First Quarter 2011 Results
5. Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034
6. Thoratec Announces Presentations at Upcoming Investor Conferences
7. Thoratec Corporation Authorizes $100 Million Share Repurchase Program
8. Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations
9. Thoratec Schedules Fourth Quarter Conference Call, Webcast
10. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
11. Thoratec Announces Webcast of Investor Presentation at American Heart Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
Breaking Medicine Technology:
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... The ... and other communities across eastern Texas, is launching a cooperative charity drive with the ... families. , Serving more than 50,000 individuals and families in need, the Tarrant County ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to ... Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal implants ... the first office to be chosen by the dental implant manufacturer, Straumann, to bring ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. ... and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans ... categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors ...
(Date:2/12/2016)... LUIS OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism ... of this dance is to provide a night of fun for teens with and without ... help everyone feel welcomed and included at the event. The dance will take place on ...
(Date:2/12/2016)... Sacramento CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative ... progression of dental decay. With the recent approval by the FDA, there is a ... application similar to fluoride varnish, SDF is very simple and quick to apply. The ...
Breaking Medicine News(10 mins):